Toll Free: 1-888-928-9744

Fibrosarcoma - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 44 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Fibrosarcoma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Fibrosarcoma - Pipeline Review, H2 2014', provides an overview of the Fibrosarcoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fibrosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosarcoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Fibrosarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Fibrosarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Fibrosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Fibrosarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Fibrosarcoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Fibrosarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Fibrosarcoma Overview 6
Therapeutics Development 7
Pipeline Products for Fibrosarcoma - Overview 7
Pipeline Products for Fibrosarcoma - Comparative Analysis 8
Fibrosarcoma - Therapeutics under Development by Companies 9
Fibrosarcoma - Therapeutics under Investigation by Universities/Institutes 10
Fibrosarcoma - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Fibrosarcoma - Products under Development by Companies 13
Fibrosarcoma - Products under Investigation by Universities/Institutes 14
Fibrosarcoma - Companies Involved in Therapeutics Development 15
Novartis AG 15
Plexxikon Inc. 16
Rigontec GmbH 17
Sumitomo Dainippon Pharma Co., Ltd. 18
Fibrosarcoma - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 25
Drug Profiles 27
DSR-6434 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
everolimus - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ImOl-100 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
KRA-0008 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
LK-3 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
PLX-7486 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Fibrosarcoma - Recent Pipeline Updates 37
Fibrosarcoma - Dormant Projects 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44
List of Tables
Number of Products under Development for Fibrosarcoma, H2 2014 7
Number of Products under Development for Fibrosarcoma - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Fibrosarcoma - Pipeline by Novartis AG, H2 2014 15
Fibrosarcoma - Pipeline by Plexxikon Inc., H2 2014 16
Fibrosarcoma - Pipeline by Rigontec GmbH, H2 2014 17
Fibrosarcoma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 18
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 23
Number of Products by Stage and Route of Administration, H2 2014 24
Number of Products by Stage and Molecule Type, H2 2014 26
Fibrosarcoma Therapeutics - Recent Pipeline Updates, H2 2014 37
Fibrosarcoma - Dormant Projects, H2 2014 42 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify